Enlivex Therapeutics Ltd Stock Price, News & Analysis

Enlivex Therapeutics (NASDAQ: ENLV) announced the closure of a public offering of 2,296,107 ordinary shares priced at $20.00 each, generating approximately $45.92 million in gross proceeds. The offering was managed by H.C. Wainwright & Co., which also received a 30-day option to purchase an additional 344,416 shares. Enlivex plans to allocate the net proceeds towards clinical, regulatory, and research activities, as well as potential acquisitions. The company operates under a shelf registration statement with the SEC.

Enlivex Therapeutics (NASDAQ: ENLV) announced an increase in its public offering to 2,296,107 ordinary shares, priced at $20.00 each, due to high demand. The offering is expected to close around February 12, 2021, pending customary closing conditions. Gross proceeds are projected to be approximately $46 million, which will be utilized for clinical, regulatory, and research activities, among other corporate purposes. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced an underwriting agreement with H.C. Wainwright & Co. to issue 500,000 ordinary shares at $20.00 each, aiming for gross proceeds of $10 million. The offering is set to close around February 12, 2021, subject to customary conditions. The underwriter also has a 30-day option for an additional 75,000 shares. Proceeds will fund clinical and regulatory activities, potential acquisitions, and general corporate purposes. This offering falls under a previously filed shelf registration statement with the SEC, providing liquidity for future endeavors.

Enlivex Therapeutics announced positive results from a Phase II clinical trial of Allocetra^TM in severe and critical COVID-19 patients. The trial, which treated 16 patients, showed 0% mortality at day-28 and 87.5% recovery rate. The average hospitalization duration post-treatment was 5.3 days. Based on these outcomes, the trial was concluded early to expedite regulatory submissions. Enlivex is optimistic about Allocetra^TM's potential in treating severe COVID-19 and other conditions associated with dysfunctional macrophages.

Enlivex Therapeutics (Nasdaq: ENLV) announced its participation at the H.C. Wainwright BioConnect 2021 Virtual Conference, with on-demand presentations available starting January 11, 2021, at 6:00 a.m. ET. The company's lead product, Allocetra^TM, is an off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state, targeting diseases like solid cancers and sepsis. This innovative approach aims to address significant unmet medical needs.

Enlivex Therapeutics has reported promising results from a Phase Ib trial of Allocetra^TM for severe sepsis. Comparing 10 treated patients to 37 matched controls revealed significant benefits: zero mortality in the treated group versus 27% in controls, a 58% reduction in ICU stay (4.7 vs. 11.1 days), and no increase in organ-failure among treated patients. The trial confirms Allocetra^TM as a safe and potentially effective treatment option for sepsis, a condition currently lacking effective therapies. Full data is available on medRxiv.org.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a new patent from the China National Intellectual Property Administration for its immunotherapy product, Allocetra^TM. This patent strengthens the Company's intellectual property rights in China by covering methods, uses, and pharmaceutical compositions associated with Allocetra^TM, aimed at treating life-threatening conditions such as sepsis and COVID-19. Enlivex focuses on developing immunotherapies for unmet medical needs, particularly in organ dysfunction and cancer therapies.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive interim results from its Phase II clinical trial of Allocetra^TM in severe and critical COVID-19 patients. Out of eight treated patients, seven fully recovered and were discharged within an average of 4.7 days, while one patient improved from critical to moderate/severe. The treatment was well tolerated with no serious adverse events reported. The trial is part of a multi-center study aimed at evaluating Allocetra^TM alongside standard care for the target patient population.

Enlivex Therapeutics has announced a positive clinical outcome for a 70-year-old patient with erosive osteoarthritis treated with Allocetra™. After five weekly infusions, the patient showed significant improvement, including a 93% reduction in CRP levels and no need for re-hospitalization over 24 months. This case marks a notable achievement in treating a rare disease with no effective options. Allocetra™ is also undergoing clinical studies for other conditions, including COVID-19.